In cancer, abnormal signaling pathways often drive uncontrolled cell growth and survival. Ligands can modulate these pathways by binding to specific receptors on the surface of cancer cells. For example, the binding of growth factors to their receptors can promote tumor growth. Conversely, blocking these interactions with therapeutic ligands can inhibit cancer progression.
